RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:284400

Small cell carcinoma of the bladder

low confidenceDisorder

Also known as: Poorly differentiated neuroendocrine carcinoma of the bladder · SCCB · Small cell bladder cancer · Small cell bladder carcinoma · Small cell carcinoma of the urinary bladder

Publications

622

Trials

6

Interventional, condition-specific

Researchers

1,293

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Small cell carcinoma of the bladder (SCCB) is a very rare, poorly differentiated neuroendocrine epithelial bladder tumor characterized clinically by hematuria and/or dysuria and a highly aggressive course.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (10)

bladder small cell neuroendocrine cancer · bladder small cell neuroendocrine carcinoma · poorly differentiated neuroendocrine carcinoma of the bladder · small cell bladder cancer · small cell bladder carcinoma · small cell carcinoma of the urinary bladder · small cell carcinoma of urinary bladder · small cell neuroendocrine carcinoma of the urinary bladder · small cell neuroendocrine carcinoma of urinary bladder · urinary bladder small cell carcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    622 matched papers (324 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    6 matched on ClinicalTrials.gov (4 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

622

622 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

622 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

324 in the last 10 years · low confidence

Phrase hits: 622 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,293

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Cheng L8 papers · 2020

    Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: liang_cheng@yahoo.com.

    Papers in Europe PMC
  2. 02
    Lopez-Beltran A7 papers · 2018

    Unit of Anatomical Pathology, Department of Surgery, Faculty of Medicine, Cordoba, Spain; Champalimaud Clinical Center, Lisbon, Portugal.

    Papers in Europe PMC
  3. 03
    Wang J7 papers · 2025

    Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, Zhejiang, China.

    Papers in Europe PMC
  4. 04
    Akbulut D6 papers · 2025

    Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD.

    Papers in Europe PMC
  5. 05
    Apolo AB6 papers · 2025

    Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: andrea.apolo@nih.gov.

    Papers in Europe PMC
  6. 06
    Gurram S6 papers · 2025

    Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

    Papers in Europe PMC
  7. 07
    Al-Ahmadie H5 papers · 2024

    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: alahmadh@mskcc.org.

    Papers in Europe PMC
  8. 08
    Boudjadi S5 papers · 2025

    Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

    Papers in Europe PMC
  9. 09
    Chandran E5 papers · 2025

    Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

    Papers in Europe PMC
  10. 10
    Choi W5 papers · 2024

    Departments of Urology.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

6

interventional trials for this specific condition

6 interventional trials matched this specific condition name; 4 currently recruiting in our sample. 319 trials are registered for small cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

6 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 89th percentile).

low confidence · 89th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

6 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: small cell carcinoma

319

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Small cell carcinoma of the bladder" OR "Small cell carcinoma of bladder" OR "Poorly differentiated neuroendocrine carcinoma of the bladder" OR "Poorly differentiated neuroendocrine carcinoma of bladder" OR "Small cell bladder cancer" OR "Small cell bladder carcinoma" OR "Small cell carcinoma of the urinary bladder" OR "Small cell carcinoma of urinary bladder" OR "bladder small cell neuroendocrine cancer" OR "bladder small cell neuroendocrine carcinoma" OR "small cell neuroendocrine carcinoma of the urinary bladder" OR "small cell neuroendocrine carcinoma of urinary bladder" OR "urinary bladder small cell carcinoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Small cell carcinoma of the bladder" OR "Small cell carcinoma of bladder" OR "Poorly differentiated neuroendocrine carcinoma of the bladder" OR "Poorly differentiated neuroendocrine carcinoma of bladder" OR "Small cell bladder cancer" OR "Small cell bladder carcinoma" OR "Small cell carcinoma of the urinary bladder" OR "Small cell carcinoma of urinary bladder" OR "bladder small cell neuroendocrine cancer" OR "bladder small cell neuroendocrine carcinoma" OR "small cell neuroendocrine carcinoma of the urinary bladder" OR "small cell neuroendocrine carcinoma of urinary bladder" OR "urinary bladder small cell carcinoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 6 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"small cell carcinoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: SCCB

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (622) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T12:06:00.908Z